Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod in Advanced Solid Tumors
NCT01743469Phase 2Completed
- Sponsor
- Ipsen
- Start
- Dec 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of tasquinimod in hepatocellular carcinoma (HCC), ovarian carcinoma, renal cell carcinoma (RCC) and 1 more (4 cohorts), sponsored by Ipsen. Primary endpoint: Progression Free Survival Rate at 24 weeks. Started Dec 2012; status: completed.
02
Drugs
tasquinimod
03
Conditions
hepatocellular carcinoma (HCC)ovarian carcinomarenal cell carcinoma (RCC)Gastric carcinoma (GC)
Beyond the preview
Go deeper on NCT01743469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743469.